Health Care Supplies

Allmed Medical

Allmed Medical released FY2025 Annual Earnings on April 27 After-Market (BJT), Actual Revenue CNY 3.672 B, Actual EPS CNY 0.4022

Allmed Medical released FY2025 Q4 earnings on April 27 After-Market (BJT), actual revenue CNY 1.075 B, actual EPS CNY -0.1725

Allmed Medical released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 896.09 M, actual EPS CNY 0.177

Allmed Medical to Release FY2026 Q1 Earnings on April 28 After-Market (BJT)

Allmed Medical to Release FY2025 Annual Earnings on April 28 After-Market (BJT)

Allmed Medical released FY2025 Q3 earnings on October 29 After-Market (BJT), actual revenue CNY 920.27 M, actual EPS CNY 0.2359

Allmed Medical released FY2025 9 Months Earnings on October 29 After-Market (BJT), with actual revenue of CNY 2.597 B and EPS of CNY 0.552

Allmed Medical to Release FY2025 Q3 Earnings on October 30 After-Market (BJT)

Allmed Medical released FY2025 Semi-Annual earnings on August 26 Pre-Market (BJT), actual revenue CNY 1.676 B, actual EPS CNY 0.316

Allmed Medical released FY2025 Q2 earnings on August 26 Pre-Market BJT, actual revenue CNY 917.68 M, actual EPS CNY 0.1794

Allmed Medical to Release FY2025 Semi-Annual Earnings on August 27, 2025, BJT

Ou Mei Medical Responds to Investor Repurchase Plan

AOMEI Medical Shareholder Chen HaoHua Plans to Reduce Shareholding

AOMEDICAL Registers New Neurosurgical Control System Software Copyright

AOMEI Medical Reports 1.64% Revenue Growth but 7.86% Net Profit Decline in Q1 2025

Aomei Medical's Net Profit Soars 233.95% in 2024

Allmed Medical released FY2024 Q4 earnings on April 25 After-Market BJT, actual revenue CNY 876.22 M, actual EPS CNY 0.1667

Allmed Medical released FY2025 Q1 earnings on April 25 After-Market BJT, actual revenue CNY 758.66 M, actual EPS CNY 0.1366

Allmed Medical released FY2024 Annual Earnings on April 25 After-Market (BJT), with actual revenue of CNY 3.326 B and EPS of CNY 0.5899

Allmed FY2025 Q1 Earnings Release on April 28 After-Market BJT

688610

002950

300819

002349

As global markets show resilience with notable gains, investor sentiment has shifted positively, creating opportunities to identify undervalued stocks. The report highlights top 10 undiscovered gems with strong fundamentals, including Jinghua Pharmaceutical Group and Hefei I-TEK OptoElectronics, which have shown impressive earnings growth and improved financial health. Companies like Allmed Medical Products and Jiangsu Jujie Microfiber Technology Group also demonstrate strong operational performance and potential for future growth. The overall environment is favorable for discovering promising investment opportunities in the stock market.

Simplywall

I-TEK

J-Micro

JINGHUA PHARM

Discovering Undiscovered Gems in Global for April 2026

301122

300453

002382

300677

300981

A-share medical consumables stocks continue to rise, ZHYL and INTCO are approaching a 20% limit-up, Allmed Medical and BLUE SAIL MEDICAL previously hit the limit-up, Sanxin Medtec and CAINA have leading gains

Wallstreetcn

CAINA

Sanxin Medtec

BLUE SAIL MEDICAL

INTCO

ZHYL

002038

512290

000963

On January 31, according to the National Healthcare Security Administration, the new national medical insurance drug list will be fully implemented in Guangxi starting from January 1, 2026. In this adjustment of the list, the National Healthcare Security Administration has included "Deferasirox Tablets" in the national medical insurance drug list through negotiations, effectively addressing the medical needs of patients with thalassemia and reducing the medication burden on insured patients' families. Before being included in medical insurance, urban and rural residents' patients incurred nearly 3,000 yuan in out-of-pocket expenses per month for treatment at designated institutions in cities and counties. After being included in medical insurance, the negotiated price reduction combined with medical insurance reimbursement means that individuals only need to pay one-tenth of the original amount

36Kr

SL PHARM

Guotai CSI Bio-medicine ETF

HUADONG MEDICINE

Hwabao WP CSI Pharmaceuticals ETF

ChinaAMC SSE STAR Biology and Medicine ETF

CISEN

ChinaAMC SSE Health Care ETF Initiating Fund

huahaipharm

E Fund CSI 300 Health Care ETF

E Fund CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

National Healthcare Security Administration: Key drug "Deferasirox" for treating "thalassemia" included in medical insurance

On October 29th, Allmed Medical released its Q3 2025 report, showing a third-quarter operating revenue of 920 million yuan, a year-on-year increase of 5.97%; net profit of 149 million yuan, a year-on-year increase of 90.57%. For the first three quarters of 2025, operating revenue was 2.597 billion yuan, a year-on-year increase of 5.98%; net profit was 349 million yuan, a year-on-year increase of 31.54%; basic earnings per share were 0.5519 yuan

Zhitong

Allmed Medical: Net profit in the third quarter was 149 million yuan, a year-on-year increase of 90.57%

Allmed Medical announced that as of October 16, 2025, major shareholder Chen Haohua, holding more than 5% of shares, has reduced his holdings by 11.6969 million shares through block trades from July 21 to 30, 2025, accounting for 1.89% of the total share capital, with an average reduction price of 8.41 yuan and a price range of 8.3 yuan to 8.53 yuan; after the reduction, he holds 61.3534 million shares, accounting for 9.92% of the total share capital, and this reduction plan has been completed

Allmed Medical: Chen Haohua has reduced his holdings by 1.89%

36Kr learned that Allmed Medical responded on the interactive platform that the company's operations are normal, order conditions are normal, and the existing production capacity can meet market demand

Allmed Medical: Existing production capacity can meet market demand

Allmed Medical announced that in the first half of 2025, operating revenue reached 1.676 billion yuan, a year-on-year increase of 5.99%. Net profit was 200 million yuan, a year-on-year increase of 6.87%. The company plans not to distribute cash dividends, not to issue bonus shares, and not to convert reserves into share capital

Allmed Medical: Net profit of 200 million yuan in the first half of 2025, a year-on-year increase of 6.87%

According to the Zhitong Finance APP, Allmed Medical announced that shareholder Chen Haohua, who holds 11.81% of the shares, plans to reduce his holdings by no more than 18.5627 million shares (not exceeding 3% of the total share capital) within three months after the announcement date, starting from fifteen trading days after the disclosure

Allmed Medical shareholder Chen Haohua plans to reduce his holdings by no more than 3%

Allmed announced that its revenue for the first quarter of 2025 was 759 million yuan, a year-on-year increase of 1.64%; net profit was 86.5027 million yuan, a year-on-year decrease of 7.86%

Allmed: Net profit in the first quarter of 2025 was 86.5027 million yuan, a year-on-year decrease of 7.86%

Allmed announced that its operating revenue for 2024 is expected to be 3.326 billion yuan, a year-on-year increase of 20.66%. The net profit attributable to shareholders of the listed company is expected to be 369 million yuan, a year-on-year increase of 233.95%. The basic earnings per share is expected to be 0.5899 yuan/share, a year-on-year increase of 238.44%. The company plans to distribute a cash dividend of 0.6 yuan for every 10 shares to all shareholders, with no bonus shares issued and no capital reserve converted into share capital

Allmed: In 2024, the net profit is 369 million yuan, a year-on-year increase of 233.95%

Allmed Medical(002950.SZ)